Salvage treatment in <em>IDH1</em> mutated acute lymphoblastic leukemia with venetoclax plus methotrexate and pegaspargase: A case report

Dan Li; Shuqi Zhao; Liping Mao; Jie Jin; Jinghan Wang

doi:10.1016/j.gendis.2023.02.011

您当前的位置：

首页 >

文章列表页 >

Salvage treatment in IDH1 mutated acute lymphoblastic leukemia with venetoclax plus methotrexate and pegaspargase: A case report

Rapid Communications | 更新时间：2024-02-04

- Salvage treatment in IDH1 mutated acute lymphoblastic leukemia with venetoclax plus methotrexate and pegaspargase: A case report
- Salvage treatment in IDH1 mutated acute lymphoblastic leukemia with venetoclax plus methotrexate and pegaspargase: A case report
- Genes & Diseases 2023年1卷第6期页码：2215-2217
- 作者机构：
  
  1. Department of Hematology, Shaoxing People's Hospital,Zhejiang,Shaoxing,China,312000
  2. Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine,Zhejiang,Hangzhou,China,310003
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2023.02.011
  中图分类号：
- 纸质出版日期：2023，
  
  网络出版日期：2023-11-1，
扫描看全文
Salvage treatment in IDH1 mutated acute lymphoblastic leukemia with venetoclax plus methotrexate and pegaspargase: A case report[J]. Genes & Diseases, 2023,1(6):2215-2217.

Dan Li, Shuqi Zhao, Liping Mao, et al. Salvage treatment in IDH1 mutated acute lymphoblastic leukemia with venetoclax plus methotrexate and pegaspargase: A case report[J]. Genes & Diseases, 2023,1(6):2215-2217.
Salvage treatment in IDH1 mutated acute lymphoblastic leukemia with venetoclax plus methotrexate and pegaspargase: A case report[J]. Genes & Diseases, 2023,1(6):2215-2217. DOI： 10.1016/j.gendis.2023.02.011.

Dan Li, Shuqi Zhao, Liping Mao, et al. Salvage treatment in IDH1 mutated acute lymphoblastic leukemia with venetoclax plus methotrexate and pegaspargase: A case report[J]. Genes & Diseases, 2023,1(6):2215-2217. DOI： 10.1016/j.gendis.2023.02.011.

摘要

Abstract

关键词

Keywords

references

1 T. Yasuda, M. Sanada, M. Kawazu, et al.Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations Blood, 139 (12) (2022), pp. 1850-1862

2 C.L. Jones, B.M. Stevens, D.A. Pollyea, et al.Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells Cell Stem Cell, 27 (5) (2020), pp. 748-764.e4

3 C.L. Jones, B.M. Stevens, A. D'Alessandro, et al.Inhibition of amino acid metabolism selectively targets human leukemia stem cells Cancer Cell, 34 (5) (2018), pp. 724-740.e4

4 A. Emadi, B. Kapadia, D. Bollino, et al.Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia Leukemia, 35 (7) (2021), pp. 1907-1924

5 W.H. Tong, R. Pieters, W.C.J. Hop, et al.No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy Pediatr Blood Cancer, 60 (2) (2013), pp. 258-261

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据

Salvage treatment in IDH1 mutated acute lymphoblastic leukemia with venetoclax plus methotrexate and pegaspargase: A case report

Salvage treatment in IDH1 mutated acute lymphoblastic leukemia with venetoclax plus methotrexate and pegaspargase: A case report

DOI：10.1016/j.gendis.2023.02.011

摘要

Abstract

关键词

Keywords

references